Abstract
CD30 is a therapeutic target in the management of patients with elapsed/refractory (R/R) Hodgkin lymphoma (HL) and systemic naplastic large-cell lymphoma (sALCL). Brentuximab vedotin has emonstrated efficacy in the management of patients with R/R HL nd sALCL, and may potentially be relevant in the management of ther CD30+ lymphomas. This webcast is of a satellite symposium hat takes the form of a forum and serves as a platform for lookng at the latest clinical trials and exchanging information on the aily management of CD30+ lymphomas. It includes several case nd panel discussions, as well as some interactive dialogue with he audience. Discussions include current medical needs in the treatment of D30+ haematological malignancies and current ongoing clinical rial data (including efficacy and safety) on novel treatment strateies for patients with HL, sALCL, and peripheral T-cell lymphoma PTCL). The selection of eligible patients and optimal management f patients with R/R HL or sALCL receiving brentuximab vedotin n daily practice are addressed, including patient eligibility, dosng, optimal number of cycles, retreatment, and the management f side effects. Ongoing clinical trials in the use of CD30-targeted
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
